Celldex Therapeutics files Form 13G reporting stake on May 15

Form 13G for Celldex Therapeutics (CLDX) was filed on 15 May 2026, reporting a beneficial-ownership disclosure under the 13G regime. Investing.com reported the filing on 15 May 2026. The notice itself — not covered here in full — is the primary source for exact ownership numbers and any amendments. Investors and desks should consult the filing for the precise percent and filer identity before acting.

What does a Form 13G indicate for Celldex shareholders?

A Form 13G signals a reported stake that is treated as passive under SEC rules and is commonly used when ownership equals or exceeds the 5% reporting threshold. The form lists the amount beneficially owned and the percent of class; the 5% figure is the statutory trigger for the schedule. A standalone 13G does not, by itself, announce activist intentions or operational control.

Portfolio managers focus on the disclosed percent and any change rows. A change in ownership reported in the form will show the date of acquisition and the exact number of shares; those figures determine voting and economic exposure.

Who can file a Form 13G and what deadlines apply?

Institutional and passive investors file a 13G when their ownership meets reporting thresholds and they do not intend to influence control. For passive filings tied to year-end holdings, the initial window is commonly 45 days after year-end, while a Schedule 13D requires filing within 10 calendar days when activist intent exists.

Different investor categories have distinct timing requirements and safe-harbor criteria; confirm the filer category inside the document. The reported filing date, 15 May 2026, is the key timestamp for any subsequent amendments.

How might markets react to a Celldex 13G?

A 13G alone typically produces muted price response unless the disclosed stake is large relative to the company's free float or is accompanied by a 13D or earnings/clinical news. Market impact assessments often treat 5% as the baseline level that attracts attention from sell-side desks and liquidity providers.

Trading desks will watch volume and the percent-of-class disclosed. If a filing shows a creeping increase in ownership across multiple filings, desks may reprice liquidity assumptions and reprioritize block execution strategies.

Where to verify this Form 13G and what to read first?

The definitive copy of any 13G appears on SEC EDGAR under the issuer or filer name; search by company ticker CLDX or by filing date 15 May 2026. Look first at the 'Amount beneficially owned' line and the 'Percent of class' field for the single most actionable numbers.

For institutional workflows, add the filing to your regulatory watchlists and cross-check the filer identity, voting power, and any joint-owner disclosures. For broader context, catalog this notice within your regulatory filings and consult our equities coverage for company fundamentals.

Limitations and risk: this note does not reproduce the filing text and does not claim the exact ownership percentage or filer identity; the original 13G and any amendments are the authoritative records and can change after initial publication.

Q: Does a Form 13G mean the filer is passive?

Yes. A 13G is the disclosure route for holders that declare passive intent while meeting the 5% reporting threshold. If the holder abandons passive status or expresses intent to influence management, a Schedule 13D — filed within 10 calendar days of the change — becomes mandatory.

Q: How can I obtain the full filing and confirm numbers quickly?

Retrieve the complete filing on SEC EDGAR by searching for Celldex Therapeutics or ticker CLDX and the filing date 15 May 2026; EDGAR provides the exact share count, percent of class, and filer identity necessary for compliance checks and position reconciliation.

Bottom Line

A Form 13G filed on 15 May 2026 signals a reported passive stake meeting the 5% disclosure threshold; consult EDGAR for exact figures.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.